Lipids and Coronary Artery Disease - The Standard of Preventive Strategies;Lipide und KHK: Standard präventiver Strategien

Munchener Medizinische Wochenschrift

Volumn 139, Issue 1-2, 1997, Pages 3-8

  Windler, E ^a   Klose, G ^b   Greten, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Medizinische Klinik   (Germany)

Author keywords

Cholesterol; Coronary Artery Disease Prevention; Lipid Lowering

Indexed keywords

EID: 0013624467     PISSN: 03413098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit. med. J. 308 (1994) 81-99.
2. Assmann, G. (ed.): Lipid Metabolism Disorders and Coronary Heart Disease. MMV Medizin Verlag, München 1993.
3. Brown, B. G., Zhao, X.-O., Sacco, D. E., Albers, J. J.: Lipid Lowering and Plaque Regression: New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease. Circulation 87 (1993) 1781-1791.
4. Cremer, P., Nagel, D., Labrot, B. et al.: Göttinger Risiko-, Inzidenz- und Prävalenzstudie (GRIPS). Springer, Heidelberg 1991.
5. Eliav, O., Schurr, D., Pfister, P., Friedlander, Y., Leitersdorf, E.: High-Dose Fluvastatin and Bezafibrate Combination Treatment for Heterozygous Familial Hypercholesterolemia. Amer. J. Cardiol. 76 (1995) 76-79A.
6. Ericsson, C.-G., Hamsten, A., Nilsson, J., Grip, L., Svane, B., de Faire, U.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. The bezafibrate coronary atherosclerosis intervention trial (BECAIT). Lancet 347 (1996) 849-853.
7. Fuster, V., Badimon, L., Badimon, J. J., Chesebro, J. H.: The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New Engl. J. Med. 326 (1992) 310-318.
8. 7a. Giroud, D., Li, J. M., Urban, P., Meier, B., Rutishauser, W.: Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Amer. J. Cardiol. 69 (1992) 729-732.
9. Gould, K. L., Martucci, J. P., Goldberg, D. I., et al.: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 89 (1994) 1530-1538.
10. Haasis, R., Berger, J.: Fluvastatin versus Lovastatin eine randomisierte, doppelblinde, multizentrische Parallelgruppenstudie zur Effektivität und Sicherheit einer Lipidsenkung. Herz Kreislauf 27 (1995) 375-380.
11. ISIS-4 Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685.
12. Keen, H., Jarrett, R. J: The WHO multinational study of vascular disease in diabetes. 2. Macrovascular disease prevalence. Diabetes Care 2 (1979) 187-195.
13. Keys, A., Menotti, A., Aravanis, C., et al.: The seven countries study: 2.289 deaths in 15 years. Prevent. Med. 13 (1984) 141-154.
14. Law, M. R., Wald, N. J., Thompson, S. G.: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Brit. med. J. 308 (1994) 367-372.
15. Leren, P.: Hypertension: The Coronary Heart Disease Dilemma. Atheroscler. Rev. 21 (1990) 195-200.
16. Löwel, H., Lewis, M., Keil, U., et al.: Zeitliche Trends von Herzinfarktmorbidität, -mortalität, 28-Tage-Letalität und medizinischer Versorgung. Z. Kardiol. 84 (1995) 596-605.
17. Ornish, D., Brown, S. E., Scheerwitz, L. W., et al.: Can lifestyle changes reverse coronary heart disease? - The Lifestyle Heart Trial. Lancet 336 (1990) 129-133.
18. Pedersen, T. R., Kjekshus, J., Berg, K., et al. for the 4S Group: Cholesterol Lowering and the Use of Healthcare Resources - Results of the Scandinavian Simvastatin Survival Study. Circulation 93 (1996) 1796-1802.
19. Pedersen, T. R., Olsson, A. G., Færgeman, O., Berg, K., Miettinen, T., Wedel, H. for the 4S Group: Simva- statin-induced Reduction in Risk of Major Coronary Events is Related to Both Reduction in LDL-Cholesterol and Increase in HDL-Cholesterol. Circulation 92 (1995) 1-198.
20. Pétursson, M. K., Jónmundsson, E. H., Brekkan, A., Hardarson, T.: Angiographie predictors of new coronary occlusions. Amer. Heart. J. 129 (1995) 515-520.
21. Rosenberg, L., Palmer, J. R., Shapiro, S.: New Engl. J. Med. 322 (1990) 213-217.
22. Sacks, F. M., Rouleau, J.-L., Moye, L. A., et al. for the CARE Investigators: Baseline Characteristics in the Cholesterol and Recurrent Events (CARE) Trial of Secondary Prevention in Patients With Average Serum Cholesterol Levels. Amer J Cardiol 75 (1995) 621-623.
23. Scandinavian Simvastatin Survival Study Group: Lancet 344 (1994) 1383-1389.
24. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. H., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., Packard, C. J., for the West of Scotland Coronary Prevention Study Group: New Engl. J. Med. 333 (1995) 1301-1307.
25. Steinberg, D.: J. intern. Med. 233 (1993) 227-232.
26. Stephens, N. G., Parxons, A., Schofield, P. M., et al.: Lancet 347 (1996) 781-786.
27. Tengs, T. O., Adams, M. E., Pliskin, J. S., et al.: Risk Analysis 15 (1995) 369-390.
28. The Beta-Blocker Pooling Project Research Group: Europ. Heart J. 9 (1988) 8-16.
29. Watts, G. F., Jackson, P., Mandalia, S., et al.: Amer. J. Cardiol. 73 (1994) 328-332.
30. Zavoral, J. H., Haggerty, B. J., Winick, A. G., Bergmann, S. D., FLUENT Study Group: Amer. J. Cardiol. 76 (1995) 37A-40A.
31. Zeiher, A. M., Schaechlinger, V., Hohnloser, S. H., Saurbier, B., Just, H.: Circulation 89 (1994) 2525-2532.